Author

S. Haricharan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Mazumder· 3 shared A. Jimenez· 1 shared C.-H. Chen· 1 shared D. Lozano· 1 shared E. Guerini-Rocco· 1 shared E. Mane· 1 shared E. Oropeza· 1 shared E. Sajjadi· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Mazumder

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Aberrant cytoplasmic localization of MLH1 characterizes a sub-clonal breast cancer cell population that seeds recurrence

A. Mazumder, T. DeWitt, E. Oropeza, N. Punturi, D. Lozano, E. Sajjadi, E. Guerini-Rocco, K. Venetis, M. Ivanova, E. Mane, N. Fusco, S. Haricharan

This study identifies aberrant cytoplasmic MLH1 localization in sub-clonal breast cancer cells as a driver of endocrine resistance, showing it predicts response to CDK4/6 inhibitors.

bioRxiv · Feb 27, 2024 · PreprintCancer Biology

Race specific differences in DNA damage repair dysregulation in breast cancer and association with outcome

A. Mazumder, A. Jimenez, R. Ellsworth, S. Freedland, S. George, M. Bainbridge, S. Haricharan

The paper identifies race-specific DNA damage repair (DDR) gene dysregulation patterns in African American (AA) ER+ breast cancer patients and links them to poorer survival outcomes.

bioRxiv · Oct 26, 2020 · PreprintCancer Biology

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

N. B. Punturi, S. Seker, V. Devarakonda, R. Kalra, C.-H. Chen, A. Mazumder, S.-Q. Li, T. Primeau, M. J. Ellis, S. M. Kavuri, S. Haricharan

This study shows that loss of MLH1, a mismatch repair gene, activates HER2 in ER+/HER2- breast cancer, making these cells sensitive to HER2 inhibitors.

bioRxiv · Jun 8, 2020Cancer Biology